It is increasingly being acknowledged that complex carbohydrates mediate a huge variety of cellular interactions, permitting and regulating recognition and signalling events. This is achieved by the enormous range and complexity of branched structures in glycoconjugates and the ability of carbohydrate-binding proteins (lectins) to decipher this 'glycocode'. Approx. 120 participants attended the 23rd International Lectin Meeting (Interlec-23) held at the Universities of Edinburgh (2 days) and Stirling (4 days) between 11 and 16 July 2008. These 'Interlecs' are truly international multi-disciplinary symposia, providing opportunities for scientists from different backgrounds, but with a common interest in some aspect of protein-carbohydrate interactions, to present their work in an informal and stimulating atmosphere. A major aim is always to induce cross-fertilization of ideas and concepts, and Interlec-23 was intended to have some bias towards lectins (galectins, collectins, selectins, siglecs etc.) and their ligands in human health and disease. Delegates from over 30 countries attended this meeting which was divided into seven oral sessions opened by a keynote speaker. This issue of Biochemical Society Transactions contains papers based on the keynote lectures and is therefore representative of the main themes of Interlec-23.
(antigen receptor non-specific) mitogens for lymphocyes and tools to distinguish malignant cells from their normal counterparts, leading to useful applications such as karyotyping and cell separation in the context of bone marrow transplantation. The discoveries of bacterial surface lectins and of lectinophagocytosis emphasized the importance of lectin-carbohydrate interactions in human health and disease, and the extensive studies of certain groups of animal lectins in the last two decades has strongly reinforced this perception.
In the future, we may expect to find exciting developments in such fields as glycomimetics, glycoform-based diagnosis of disease, glycoform-based cancer therapy and lectinreplacement therapy for deficiency states.
Galectins as molecular scaffolds
Galectins are a structurally homologous group of β-galactoside-binding proteins with a tertiary structure that has much in common with both legume lectins and vertebrate pentraxins. A few years ago, I wrote that galectins "are everywhere, but do nothing!" [2] . That quip was justified by the confusing situation that galectins were abundant and universal molecules in mammals with numerous fascinating properties in vitro, yet knockout mice lacking galectins-1 and -3 had a virtually normal phenotype. Even then, there was substantial evidence that galectins played a role in cell adhesion and the related functions of cellular proliferation and differentiation. Increasingly, galectins are being implicated as regulators of immunity and immune homoeostasis [5] . Linda Baum propounded the view that galectins function as scaffolding proteins on the cell surface to organize cell-surface glycoproteins into functional domains in the plasma membrane [6] . Several examples of galectin-glycan lattices regulating cellular events such as T-lymphocyte apoptosis, viral attachment to host receptors and growth factor signalling in tumour cells were mentioned. Galectin binding appears to stabilize lipid rafts, regulates signalling thresholds and alters receptor residency time at the cell surface by responding to changes in cellular glycosylation. Hans-Joachim Gabius [7] also addressed the role of galectins in cancer, giving examples from neuroblastoma, pancreatic carcinoma and colon cancer. Other speakers (Karel Smetana, Lu-Gang Yu and Cecilia Cederfur) described the prognostic value of galectins and/or galectin-binding proteins in various malignancies, where their role still appears complex and far from straightforward. For example, galectin-3 promotes the spread of colon and other cancer cells expressing MUC-1 (mucin 1), yet the presence of galectin-3-binding sites is a very good prognostic factor in head and neck squamous cell carcinoma.
Cell-surface lectins and immune regulation
It is not just galectins that regulate glycan-mediated processes at the cell surface: C-type lectins and I-type lectins play crucial regulatory roles in the immune system as well. Yvette van Kooyk and associates have pioneered work on carbohydrate recognition by endogenous dendritic cell lectins, especially MGL (macrophage galactose/N-acetylgalactosamine-specific C-type lectin) and DC-SIGN (dendritic cell-specific intracellular adhesion molecule-3 grabbing nonintegrin) [8] . Dendritic cells orchestrate the immune response and provide a bridge between the innate and adaptive immune systems. Dendritic cells synthesize a great variety of lectins, most of which belong to the many subgroups of C-type lectins, although different subsets (and dendritic cells from different species) differ in the complement of cell-surface lectins displayed. The interactions between those lectin receptors, Toll-like receptors and surface glycans on pathogens are potentially of crucial significance. Central to this work is the concept that microbial glycoconjugates instruct dendritic cell responses, influencing the nature as well as the degree of an immune response. It follows that glycans can be exploited to augment vaccination or to induce a tolerogenic T-cell response.
Another group of lectins that appear to be involved in immune regulation belong to the immunoglobulin superfamily. These I-type lectins are integral membrane proteins that possess extracellular domains with carbohydrate-recognition ability. The major subgroup is the sialic acid-specific collection of sialoadhesin-related lectins or 'siglecs' (sialic acid-binding immunoglobulin-like lectins) [9] . Paul Crocker summarized our current knowledge of human and murine members of this molecular family [9] . The 14 human siglecs are mainly found on cells of the immune system and are often considered to be negative regulators. The function of most siglecs appears to be controlled by cis-masking by endogenous ligands on the same cell. While those cis ligands down-regulate, trans binding of ligands on other cells can occur to disturb the equilibrium. Each siglec has a unique specificity for sialylated glycans, and it is assumed that each has a distinct, but overlapping, function. Progress in understanding murine siglec function is being obtained from studies of siglec-deficient knockout mice.
Collagen-related lectins in innate immunity
The collagen-related defence proteins include two groups of animal lectins: collectins and ficolins [10] . Collectins are molecules that possess both a collagen-like domain and a C-type lectin-like domain. MBL (mannan/mannose-binding lectin) is the most studied of the collectins and its wellcharacterized genetics and biochemistry were described by Peter Garred [11] . Common variant alleles situated both in the promoter and in the structural region of the human MBL-2 gene influence circulating MBL concentration. Epidemiological studies indicate that variant alleles and/or low plasma MBL concentration ('insufficiency') can influence susceptibility to and the course of numerous infections as well as certain autoimmune, neoplastic, metabolic and cardiovascular diseases. The frequent occurrence of variant alleles in many different human populations may reflect a dual role for MBL. Several recent studies indicate that high concentrations of MBL may be harmful in some contexts and that heterozygosity for MBL-2 variants (and consequent modest protein levels) can be beneficial and protective [12] .
Another approach to understanding the function of MBL and the potential of MBL replacement therapy was given an overview by Kazue Takahashi [13] . The use of double (MBL-A − /C − ) knockout mice has demonstrated unequivocally that MBL in vivo protects against Staphylococcus aureus infection. MBL-deficient mice were susceptible to intravenous infection, but not to intraperitoneal infection, unless the latter was accompanied by cyclophosphamide-induced neutropenia. This indicated not only that the route (site) of infection was important, but also that co-existing immune defects can be influential. (The latter conclusion was reinforced by the finding that MBL-deficient mice are much more susceptible than wild-type mice to Pseudomonas aeruginosa septicaemia, but only following burn injury.) Most importantly, the phenotype of the MBL-deficient mice could be reversed by administration of human recombinant MBL. Further studies on those animals have demonstrated that MBL can also mediate harmful events, including reperfusion injury after myocardial ischaemia and susceptibility to traumatic brain injury.
Only one other presentation (Rachel Lawrence) was concerned with MBL-null mice. Studying the parasitic nematode, Brugia malayi, it was found that the absence of either MBL-A or MBL-C decreased the clearance of microfilariae from the bloodstream and increased survival of the parasite in mice. However, clinical studies confirming and extending the associations between MBL deficiency and miscarriage (Ole B. Christiansen) and severe sepsis (Damon Eisen) were also presented. Several other contributions involved other collectins, including the antiviral properties of porcine surfactant protein D (Henk Haagsman), the influence of novel chicken collectins on influenza A virus (Edwin Veldhuizen) and the cloning and characterization of novel ascidian collectins (Nobutaka Wakamiya).
Ficolins were discovered long after the collectins and have been studied less intensively [14] . Few clinical association studies have been published [15] , but several were presented at Interlec-23. James Chalmers revealed data to show that relative L-ficolin deficiency is overrepresented in adult patients with stable bronchiectasis compared with blood donors or community-acquired pneumonia patients. A poster presentation by Maciej Cedzynski and co-workers reported an association between low serum L-ficolin concentrations and asthma and/or allergic rhinitis in Polish children. Another poster presentation from the same group (Ania Swierzko et al.) described a large prospective study based on umbilical cord blood samples. Relative L-ficolin deficiency was strongly and significantly associated with premature births, low birthweight and perinatal infections.
Lectins as markers and agents of disease
Since neoplastic and other diseases are often accompanied by changes in glycosylation, and since lectins detect such changes, lectins have been applied as diagnostic and prognostic reagents in pathology. Investigations in glycopathology have obvious implications for development of novel therapeutic interventions. Sugar profiling of total serum N-linked glycoproteins or of single molecules such as IgG is yielding promising results (Azita Alavi): different rheumatic diseases have different IgG sugar-prints, and total serum glycoprinting can distinguish ulcerative colitis from Crohn's disease.
Lectins present in foodstuffs can (to some extent) survive the digestive process and enter the circulation to access normally or abnormally glycosylated tissues. Current dietary recommendations inevitably promote dietary lectin intake. Jessica Kuzma outlined an ongoing clinical trial to determine whether peanut and wheatgerm agglutinins enter the human bloodstream at concentrations capable of influencing physiological functions and therefore of potentially compromising food safety. David Freed presented a scenario where dietary PNA (peanut agglutinin) interacted with glomeruli and abnormal IgA to cause IgA nephritis. Jonathan Rhodes suggested that dietary PNA could promote bowel cancer [16] . The suggested mechanism was by promoting proliferation after binding to the Thomsen-Friedenreich antigen. However, the mushroom (Agaricus bisporus) lectin binds to the same oncofetal antigen and appears to be protective in the diet by suppressing proliferation. Galactose would be expected to inhibit both of those lectins, and the protective influence of non-legume vegetables such as broccoli correlated with the galactose content of their soluble fibre [16] .
Carbohydrate oncofetal antigens continue to be a target for lectin-mediated cancer treatment. Els Van Damme described the properties of Morniga-G, one of two lectins from the bark of the mulberry tree, Morus nigra. Morniga-G exhibits a selective high affinity towards the Tn antigen expressed by many carcinomas. It is rapidly endocytosed by Jurkat cells and is highly cytotoxic towards them. It was suggested that a porphyrin-Morniga-G complex might improve the efficacy of photodynamic therapy of tumours.
Lectins galore
The focus above has been on lectin-glycan interactions of relevance to human health. There were also, however, many talks and posters describing new lectins and highlighting interesting lectin properties from plants, bacteria, invertebrates and non-human vertebrates. To give some indication of the scope, mention could be made of multiple Caenorhabditis elegans galectins (Yoko Nemoto-Sasaki), pentraxins from the Vietnamese fish, Pangasius hypophthalmus, serum (Sonia Beeckmans), lectins from lactobacilli and bifidobacteria (Vladimir Lakhtin), and an anti-tumour cell lectin from a Chinese mushroom, Pleurotus citrinopileatus (Chi-Ming Chiang).
